

Asthma Indicators for LHIN 13: North East

Indicator	Asthma Indicators for LHIN 13: North East																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	35.23	36.90	33.40	35.69	32.92	35.79	37.59	35.47	36.55	37.41	41.81	44.78	44.28	43.36	48.28	43.13	42.48	46.36	48.38	57.26	63.25	61.61	59.80
2. PFT used for monitoring (% of prevalent asthma) [†]	7.42	6.84	6.85	6.70	6.13	5.91	5.86	5.52	5.33	5.36	5.02	5.25	5.30	5.20	5.37	5.05	5.03	4.69	4.75	4.97	5.35	5.57	5.22
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	59.44	58.01	57.72	57.76	56.76	56.20	54.57	52.75	52.23	51.30	50.04	51.00	50.24	50.64	50.36	51.80	51.47	51.04	49.69	50.43	49.77	47.49	44.83
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	69.16	67.60	65.52	64.86	62.84	61.17	58.02	55.63	53.91	53.07	50.11	49.73	48.44	47.66	47.40	47.23	46.58	45.26	42.50	35.96	35.61	33.29	32.55
5. ≥1 asthma ED visit (% of prevalent asthma)	8.01	6.80	6.24	5.75	5.28	4.63	3.92	3.89	3.43	3.41	3.23	2.97	2.72	2.57	2.43	2.11	2.00	1.93	1.60	1.74	1.66	1.57	1.62
6. ≥1 asthma physician office visit (% of prevalent asthma)	36.02	32.18	29.16	28.02	25.47	24.20	22.42	20.43	19.88	18.46	17.35	16.64	14.72	13.46	12.84	11.59	10.57	10.00	9.33	9.21	8.77	8.63	8.71
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	30.84	32.40	34.48	35.14	37.16	38.83	41.98	44.37	46.09	46.93	49.89	50.27	51.56	52.34	52.60	52.77	53.42	54.74	57.50	64.04	64.39	66.71	67.45
1-2	17.02	17.26	17.76	18.96	17.85	18.05	17.53	16.90	17.66	18.15	16.83	17.27	18.17	17.87	17.22	17.28	17.64	17.44	16.84	14.72	14.80	13.43	13.58
≥3	52.13	50.33	47.76	45.90	44.99	43.12	40.50	38.74	36.25	34.93	33.27	32.46	30.27	29.80	30.18	29.95	28.93	27.82	25.66	21.25	20.81	19.87	18.97

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.